Last edition
News about "Qualified Infectious Disease Product "
BARDA Boosts Funding for Basilea's Investigational Oral Antibiotic Targeting Drug-Resistant UTIs
Basilea Pharmaceutica has secured an additional USD 5.4 million from BARDA to accelerate the development of its investigational oral antibiotic ceftibuten-ledaborbactam etzadroxil, a potential treatment for complicated urinary tract infections caused by multidrug-resistant Gram-negative pathogens.
Qualified Infectious Disease Product | 06/08/2026 | By News Bureau
BioVersys AG receives US Food and Drug Administration nod to include US patients in Phase III BV100 trial targeting drug-resistant pneumonia, marking progress in combating deadly hospital infections globally.
Qualified Infectious Disease Product | 18/03/2026 | By News Bureau | 171
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy